Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiaomei Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1924-7524; OpenAlex author ID A5101634945. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 2 papers

Papers 16

  1. A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neuron.2026.03.039↗
  2. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-026-03864-z↗
  3. Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenoc… Co-author DOI 10.1002/advs.202511726↗
  4. Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adeno… Co-author DOI 10.1002/cac2.12637↗
  5. Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosin… Last author DOI 10.1002/ctm2.70191↗
  6. OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. Co-author DOI 10.7150/thno.103494↗
  7. Retraction Note: Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-024-01383-2↗
  8. Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10142-023-01020-4↗
  9. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic … Last author DOI 10.1007/s13402-023-00824-7↗
  10. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  11. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  12. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. Co-author DOI 10.1096/fj.201901237r↗
  13. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  14. Structural diversity of anti-pancreatic cancer capsimycins identified in mangrove-derived Streptomyces xiamenensis 318 and post-modification via a novel cytoch… Co-author DOI 10.1038/srep40689↗
  15. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗
  16. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep15869↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shu‐Heng Jiang · 15 shared papers, 2015–2026 · strength 2.23
  2. Zhigang Zhang · 12 shared papers, 2015–2026 · strength 1.60
  3. Xueli Zhang · 8 shared papers, 2019–2026 · strength 1.37
  4. Li-Peng Hu · 7 shared papers, 2019–2026 · strength 1.14
  5. Hui Nie · 6 shared papers, 2019–2025 · strength 0.84
  6. Shan Zhang · 4 shared papers, 2023–2025 · strength 0.76
  7. Linli Yao · 4 shared papers, 2022–2026 · strength 0.73
  8. Dong‐Xue Li · 3 shared papers, 2025 · strength 0.63
  9. Hong‐Fei Yao · 3 shared papers, 2023–2026 · strength 0.58
  10. Dejun Liu · 3 shared papers, 2022–2026 · strength 0.53
  11. Yongwei Sun · 6 shared papers, 2015–2022 · strength 0.49
  12. Yan-Zhi Gai · 3 shared papers, 2022–2024 · strength 0.46
  13. Qing Ye · 2 shared papers, 2025–2026 · strength 0.44
  14. Qing Li · 3 shared papers, 2021–2025 · strength 0.43
  15. Yu-Heng Zhu · 2 shared papers, 2025–2026 · strength 0.41
  16. Luju Jiang · 2 shared papers, 2025–2026 · strength 0.41
  17. Shuqi Cai · 2 shared papers, 2025–2026 · strength 0.41
  18. Rong Hua · 2 shared papers, 2025–2026 · strength 0.41
  19. Hui Li · 2 shared papers, 2024–2026 · strength 0.38
  20. Qin Yang · 3 shared papers, 2019–2023 · strength 0.35
  21. Yingna Liao · 2 shared papers, 2023–2024 · strength 0.34
  22. Yan‐Miao Huo · 3 shared papers, 2015–2026 · strength 0.33
  23. Dongxue Li · 2 shared papers, 2022–2025 · strength 0.33
  24. Yifan Zhang · 2 shared papers, 2021–2022 · strength 0.23
  25. Aziguli Tulamaiti · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.